Domain Therapeutics enters into collaboration with XOMA
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies Strasbourg, France, February...
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field...
The agreement covers the creation and sale of rodent animal models, the sale of existing...
TxCell to present an innovative, personalized cell-based immunotherapy approach at the 16th BIO CEO...
TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory...
Curie-Cancer and Servier continue a renewed partnership in cancer research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers Paris...
Clasado and University of Oxford demonstrate effect of prebiotics on brain and gut in...
Study results provide positive data for ongoing human trials Reading and Oxford, UK, January...
Domain Therapeutics opens a North American subsidiary at Montreal’s NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All(TM) technologyStrasbourg, France and...
State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution...
NanoLogix Inc. an innovator in the rapid detection identification and determination of antibiotic resistance and...
Domain Therapeutics opens a North American subsidiary at Montreal’s NEOMED Institute
Strasbourg, France and Montreal, Canada, January 20, 2014 – Domain Therapeutics, a biopharmaceutical...
Otsuka Pharmaceutical’s POCARI SWEAT to Be Official Drink for Two Consecutive Asian Games
Otsuka Pharmaceutical Co. Ltd. (Head office: Chiyoda-ku Tokyo; President Representative Director: Taro Iwamoto) signed a...
